{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:50:38Z","timestamp":1782741038628,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s15010-016-0895-x","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T08:22:25Z","timestamp":1460794945000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas"],"prefix":"10.1007","volume":"44","author":[{"given":"Athena","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Bolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"895_CR1","doi-asserted-by":"crossref","first-page":"e4955","DOI":"10.1136\/bmj.e4955","volume":"345","author":"G Phoenix","year":"2012","unstructured":"Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. BMJ. 2012;345:e4955.","journal-title":"BMJ"},{"key":"895_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S095026880500484X","volume":"134","author":"SM Ellis Simonsen","year":"2006","unstructured":"Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, et al. Cellulitis incidence in a defined population. Epidemiol Infect. 2006;134:293\u20139.","journal-title":"Epidemiol Infect"},{"key":"895_CR3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jinf.2011.11.004","volume":"64","author":"CG Gunderson","year":"2012","unstructured":"Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64:148\u201355.","journal-title":"J Infect"},{"key":"895_CR4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/00365548609021656","volume":"18","author":"C Jorup-Ronstrom","year":"1986","unstructured":"Jorup-Ronstrom C. Epidemiological, bacteriological and complicating features of erysipelas. Scand J Infect Dis. 1986;18:519\u201324.","journal-title":"Scand J Infect Dis"},{"key":"895_CR5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/clinids\/23.5.1091","volume":"23","author":"B Eriksson","year":"1996","unstructured":"Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23:1091\u20138.","journal-title":"Clin Infect Dis"},{"key":"895_CR6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/00365549709011834","volume":"29","author":"P-I Bergkvist","year":"1997","unstructured":"Bergkvist P-I, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29:377\u201382.","journal-title":"Scand J Infect Dis"},{"key":"895_CR7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/B978-1-4557-4801-3.00095-3","volume-title":"Mandell, Douglas and Bennett\u2019s principles and practice of infectious diseases","author":"MS Pasternack","year":"2015","unstructured":"Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Bennet JE, Dolin R, Blaser MJ, editors. Mandell, Douglas and Bennett\u2019s principles and practice of infectious diseases, vol. 1. 8th ed. Philadelphia: Churchill Livingstone; 2015. p. 1194\u2013215.","edition":"8"},{"key":"895_CR8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","volume":"41","author":"DL Stevens","year":"2005","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein RJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373\u2013406.","journal-title":"Clin Infect Dis"},{"key":"895_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diagmicrobio.2013.02.020","volume":"76","author":"GT Ray","year":"2013","unstructured":"Ray GT, Suaya JA, Baxter R. Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Micro Inf Dis. 2013;76:24\u201330.","journal-title":"Diagn Micro Inf Dis"},{"key":"895_CR10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"MZ David","year":"2010","unstructured":"David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616\u201387.","journal-title":"Clin Microbiol Rev"},{"key":"895_CR11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jac\/dkl101","volume":"57","author":"MD Green","year":"2006","unstructured":"Green MD, Beall B, Marcon MJ, Allen CH, Bradley JS, Dashefsky B, et al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrob Chemother. 2006;57:1240\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"895_CR12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/01.SMJ.0000051060.95210.9A","volume":"96","author":"ZD Mulla","year":"2003","unstructured":"Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J. 2003;96:968\u201373.","journal-title":"South Med J"},{"key":"895_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","volume":"59","author":"JR Carapetis","year":"2014","unstructured":"Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections. Clin Infect Dis. 2014;59:358\u201365.","journal-title":"Clin Infect Dis"},{"key":"895_CR14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","volume":"55","author":"GW Amsden","year":"2005","unstructured":"Amsden GW. Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"895_CR15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciq067","volume":"52","author":"K Chua","year":"2011","unstructured":"Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician\u2019s guide to community MRSA\u2014its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52:99\u2013114.","journal-title":"Clin Infect Dis"},{"key":"895_CR16","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration. 2011. http:\/\/www.cochrane-handbook.org . Accessed Mar 2011."},{"key":"895_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2133.1992.tb08048.x","volume":"127","author":"P Bernard","year":"1992","unstructured":"Bernard P, Plantin P, Roger H, Sassolas B, Villaret E, Legrain V, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992;127:155\u20139.","journal-title":"Br J Dermatol"},{"key":"895_CR18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/IPC.0000000000000146","volume":"22","author":"MG Thomas","year":"2014","unstructured":"Thomas MG. Oral clindamycin compared with sequential intravenous and oral flucloxacillin in the treatment of cellulitis in adults. A randomized, double-blind trial. Infect Dis Clin Pract. 2014;22:330\u20134.","journal-title":"Infect Dis Clin Pract"},{"key":"895_CR19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1742-1241.1988.tb08526.x","volume":"42","author":"A Baig","year":"1988","unstructured":"Baig A, Grillage MG, Welch RB. A comparison of erythromycin and flucloxacillin in the treatment of infected skin lesions in general practice. Br J Clin Pract. 1988;42:110\u20135.","journal-title":"Br J Clin Pract"},{"key":"895_CR20","first-page":"236","volume":"12","author":"EHD Pusponegoro","year":"1990","unstructured":"Pusponegoro EHD, Wiryadi BE. Clindamycin and cloxacillin compared in the treatment of skin and soft-tissue infections. Clin Ther. 1990;12:236\u201341.","journal-title":"Clin Ther"},{"key":"895_CR21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/030006059101900602","volume":"19","author":"R Daniel","year":"1991","unstructured":"Daniel R, The European Azithromycin Study Group. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. J Int Med Res. 1991;19:433\u201345.","journal-title":"J Int Med Res"},{"key":"895_CR22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/BF01975848","volume":"10","author":"R Kiani","year":"1991","unstructured":"Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis. 1991;10:880\u20134.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"895_CR23","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1016\/0002-9343(91)90400-R","volume":"91","author":"SB Mallory","year":"1991","unstructured":"Mallory SB. Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am J Med. 1991;91:36S\u20139S.","journal-title":"Am J Med"},{"key":"895_CR24","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1093\/clinids\/14.Supplement_2.S255","volume":"14","author":"TM Nolen","year":"1992","unstructured":"Nolen TM. Clinical trials of cefprozil for treatment of skin and skin-structure infections: review. Clin Infect Dis. 1992;14:S255\u201363.","journal-title":"Clin Infect Dis"},{"key":"895_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/31.suppl_E.103","volume":"31","author":"A Rodriguez-Solares","year":"1993","unstructured":"Rodriguez-Solares A, Perez-Gutierrez F, Prosperi J, Milgram E, Martin A. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother. 1993;31:103\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"895_CR26","first-page":"837","volume":"43","author":"J Arata","year":"1995","unstructured":"Arata J, Torigoe R, Ohkawara A, Koizumi H, Sato H, Furuya K, et al. A multicenter, double-blind, double placebo clinical trial of azithromycin versus cefaclor in the treatment of skin and skin structure infections. Jpn J Chemother. 1995;43:837\u201350.","journal-title":"Jpn J Chemother"},{"key":"895_CR27","first-page":"1047","volume":"52","author":"ML Jardim","year":"1995","unstructured":"Jardim ML, Mendonca MG. Treatment of bacterial skin infections an open, randomized and comparative study among roxithromycin and cephalexin. Rev Bras Med. 1995;52:1047\u201351.","journal-title":"Rev Bras Med"},{"key":"895_CR28","first-page":"81","volume":"53","author":"LC Pereira","year":"1996","unstructured":"Pereira LC. Comparative clinical study between roxithromycin and cephalexin in the treatment of folliculitis, furunculosis and erysipelas\/cellulitis. Rev Bras Med. 1996;53:81\u20136.","journal-title":"Rev Bras Med"},{"key":"895_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/37.suppl_C.125","volume":"37","author":"L Montero","year":"1996","unstructured":"Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and\/or soft tissue infections. J Antimicrob Chemother. 1996;37:125\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"895_CR30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0011-393X(98)85036-4","volume":"59","author":"M Blaszczyk-Kostanecka","year":"1998","unstructured":"Blaszczyk-Kostanecka M, Dobozy A, Dominguez-Soto L, Guerrero R, Hunyadi J, Lopera J, et al. Comparison of two regimens of oral clindamycin versus dicloxacillin in the treatment of mild-to-moderate skin and soft-tissue infections. Curr Ther Res. 1998;59:341\u201353.","journal-title":"Curr Ther Res"},{"key":"895_CR31","first-page":"183","volume":"53","author":"J Arata","year":"2005","unstructured":"Arata J, Shimizu H, Watanabe S, Miyachi Y, Iwatsuki K, Furue M, et al. Clinical evaluation of telithromycin in patients with skin and soft tissue infections. Phase III double-blind comparative study of telithromycin versus cefdinir. Jpn J Chemother. 2005;53:183\u2013206.","journal-title":"Jpn J Chemother"},{"key":"895_CR32","first-page":"CD004299","volume":"6","author":"SA Kilburn","year":"2010","unstructured":"Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010;6:CD004299.","journal-title":"Cochrane Database Syst Rev"},{"key":"895_CR33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bmj.325.7369.864","volume":"325","author":"P Bernard","year":"2002","unstructured":"Bernard P, Chosidow O, Vaillant L, The French Erysipelas Study Group. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ. 2002;325:864.","journal-title":"BMJ"},{"key":"895_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijantimicag.2011.05.008","volume":"38","author":"RA Seaton","year":"2011","unstructured":"Seaton RA, Sharp E, Bezlyak V, Weir CJ. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents. 2011;38:243\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"895_CR35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1086\/340056","volume":"34","author":"ML Grayson","year":"2002","unstructured":"Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002;34:1440\u20138.","journal-title":"Clin Infect Dis"},{"key":"895_CR36","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1086\/521859","volume":"46","author":"RC Owens","year":"2008","unstructured":"Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19\u201331.","journal-title":"Clin Infect Dis"},{"key":"895_CR37","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","volume":"57","author":"KA Brown","year":"2013","unstructured":"Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57:2326\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"895_CR38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dku379","volume":"70","author":"J Nemeth","year":"2015","unstructured":"Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:382\u201395.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0895-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-016-0895-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0895-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-016-0895-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T20:16:13Z","timestamp":1718482573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-016-0895-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s15010-016-0895-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}